References of "DELWAIDE, Jean"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailOne year experience of the Belgian Liver Intestine Comittee (BLIC) intranet database
Lerut, Jan; Roggen, F.; De Hemptinne, Bernard et al

in Acta Gastro-Enterologica Belgica (2001, January), 64(1), 7

Detailed reference viewed: 45 (3 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation for hepatitis B virus infection: improving long-term outcomes
Detry, Olivier ULg; Delwaide, Jean ULg

in Medscape Transplantation (2001)

Detailed reference viewed: 11 (6 ULg)
Full Text
Peer Reviewed
See detailComment je traite une ascite
Gielen, S.; Delwaide, Jean ULg; Detry, Olivier ULg et al

in Revue Médicale de Liège (2001), 56(12), 809-815

Ascites is the most common of the major complications of cirrhosis. The initial evaluation of a patient with ascites should include a history, physical evaluation and some investigations. Treatment should ... [more ▼]

Ascites is the most common of the major complications of cirrhosis. The initial evaluation of a patient with ascites should include a history, physical evaluation and some investigations. Treatment should consist of treating the underlying liver disease, sodium restricted diet (2 g of Na+/day) and diuretics. This regimen is effective in 90 % of patients. The treatment options for the diuretic-resistant patients include serial therapeutic paracentesis, peritoneovenous shunting, TIPSand liver transplantation. The treatment and prophylaxis of spontaneous bacterial peritonitis which is a frequent and severe complication in cirrhotic patients with ascites is also important. The differential diagnosis with secondary bacterial peritonitisis is essential because the latter usually does not resolve unless patients are surgically treated. [less ▲]

Detailed reference viewed: 90 (4 ULg)
Full Text
Peer Reviewed
See detailFactors inftuencing ribavirin-induced hemolysis
Van Vlierberghe, H.; Delanghe, J. R.; De Vos, M. et al

in Journal of Hepatology (2001), 34

BackgroundlAims: One of the major side eft'ects of the combination therapy for chronic hepatitis C is ribavirininduced hemolytic anemia. Little is known about variables inftuencing tbis anemia. Our study ... [more ▼]

BackgroundlAims: One of the major side eft'ects of the combination therapy for chronic hepatitis C is ribavirininduced hemolytic anemia. Little is known about variables inftuencing tbis anemia. Our study tried to search for these variables in a large group of patients with hepatitis C treated with the combination therapy. Methods: Two hundred and forty-four patients chronically infected with the hepatitis C virus were treated either with induction treatment (daily dose ofinterferon) or with a standard treatment (interferon thrice weekly). Both groups received 1000-1200 mg of ribavirin from week 4 until the end of the treatment. The drop in hemoglobin level was defined as the dift'erence between the pretreatment hemoglobin level and the hemoglobin level at week 8. Seventeen variables which could possibly influencê'this drop in hemoglobin level were examined. Results: After multivariate analysis, the drop in hemoglobin level was only significant influenced by pretreatment platelet level, treatment and haptoglobin phenotype. The ribavirin dose did not influence the drop in hemoglobin level or the early virological response. Conclusions: Ribavirin-induced hemolysis is inftuenced by the pretreatment platelet level, the administered amount of a-interferon and the haptoglobin phenotype. A careful search for the minimal dose of ribavirin needed in combination treatment is necessary. [less ▲]

Detailed reference viewed: 27 (0 ULg)
Full Text
Peer Reviewed
See detailClinical biliary complications after adult liver transplantation: a prospective study
Detry, Olivier ULg; Maweja, Sylvie ULg; Delwaide, Jean ULg et al

in Acta Gastro-Enterologica Belgica (2000, March), 63(1), 56

Detailed reference viewed: 23 (5 ULg)
Peer Reviewed
See detailDaily induction combination treatment with alfa2b interferon or standard combination treatment in naive chronic hepatitis C patients. A controlled multicenter randomized trail.
Van Vlierberghe, H. R.; Leroux-Roels, F.; Bourgeois, N. et al

in Hepatology (Baltimore, Md.) (2000), 32(4), 819

Detailed reference viewed: 15 (0 ULg)
Peer Reviewed
See detailDaily induction treatment with alfa2b interferon in naive chronic hepatitis C patients results in a higher early response, a controlled multicenter randomized trial.
Van Vlierberghe, H.; Leroux-Roels, G.; Bourgeois, N. et al

in Gastroenterology (2000), 118(4), 6769

Detailed reference viewed: 12 (0 ULg)
Peer Reviewed
See detailL'image du mois. Thrombose de la veine porte
Ancion, G.; Delwaide, Jean ULg; Boverie, Jacques ULg

in Revue Médicale de Liège (2000), 55(8), 761-762

Detailed reference viewed: 28 (9 ULg)
Full Text
Peer Reviewed
See detailEvidence-Based Medicine: traitement de l'hépatite chronique C. GLEVHE. Groupe Liégeois d'Etude des Virus Hépatotropes.
Delwaide, Jean ULg; Gerard, Christiane ULg; Belaiche, Jacques ULg et al

in Revue Médicale de Liège (2000), 55(5), 337-340

The Hepatitis C virus (HCV) infects nearly 170 million people in the world. The major characteristic of virus C is its tendency to chronicity in more than 85% of cases. Generally asymptomatic, HCV ... [more ▼]

The Hepatitis C virus (HCV) infects nearly 170 million people in the world. The major characteristic of virus C is its tendency to chronicity in more than 85% of cases. Generally asymptomatic, HCV infection may also evolve with time to cirrhosis and hepatocellular carcinoma. During the last few years, HCV-related end-stage cirrhosis has become the first cause of liver transplantation. In 10 years only, very significant progress has been made in the knowledge of the virus, not only in the field of diagnosis but also in therapy. Several consensus conferences taking last discoveries into account have been organized in order to promote recommendations useful for the management of hepatitis C patients. The aim of this short overview is to summarize practical recommendations that emerged recently from consensus meetings. [less ▲]

Detailed reference viewed: 50 (6 ULg)
Peer Reviewed
See detailChronic hepatitis B therapy with lamivudine in clinical practice - Summary of the discussion
Dixon, J.; Delwaide, Jean ULg; Horsmans, Y. et al

in Acta Gastro-Enterologica Belgica (2000), 63(4), 357-358

Detailed reference viewed: 15 (1 ULg)
Full Text
See detailHépatites C sporadiques. Risque iatrogène non négligeable
Delwaide, Jean ULg

in Interface (2000), 6

On estime à plus de 150 millions le nombre d'individus infectés par le virus de l'hépatite C dans le monde. En Belgique, cette prévalence est estimée à 10/0, et la plupart des nouvelles contaminations se ... [more ▼]

On estime à plus de 150 millions le nombre d'individus infectés par le virus de l'hépatite C dans le monde. En Belgique, cette prévalence est estimée à 10/0, et la plupart des nouvelles contaminations se retrouvent chez les toxicomanes utilisant des drogues intraveineuses. Les transmissions en milieu hospitalier pourraient cependant rendre compte d'une part non négligeable des hépatites C dites «sporadiques», dont le mode de transmission n'est jusqu'ici pas élucidé. [less ▲]

Detailed reference viewed: 56 (2 ULg)
Peer Reviewed
See detailAcute pancreatitis attributed to the use of interferon alfa-2b
Eland, I. A.; Rasch, M. C.; Sturkenboom, M. J. et al

in Gastroenterology (2000), 119(1), 230-233

Two patients experienced episodes of acute pancreatitis shortly after starting treatment with interferon alfa-2b (IFN-alpha) for a chronic hepatitis C infection. The first patient was a 40-year-old man ... [more ▼]

Two patients experienced episodes of acute pancreatitis shortly after starting treatment with interferon alfa-2b (IFN-alpha) for a chronic hepatitis C infection. The first patient was a 40-year-old man who developed acute pancreatitis after 15 weeks of treatment with 3 MU IFN-alpha subcutaneously (SC) 3 times weekly and 1200 mg ribavirin. After disappearance of symptoms and normalization of laboratory values, oral intake of solid foods and IFN-alpha therapy were restarted. Within hours, a relapse of acute pancreatitis occurred. A rechallenge with IFN-alpha 4 days later was followed by a prompt increase in serum lipase level, and IFN-alpha therapy was discontinued. The second patient was a 38-year-old man who developed acute pancreatitis 2 hours after SC administration of 5 MU IFN-alpha. Ultrasound endoscopy showed sludge in the gallbladder. The patient was rechallenged 5 weeks later with 3 MU IFN-alpha SC. Although serum amylase and lipase levels increased after readministration of IFN-alpha, treatment was continued. The patient was readmitted 2 weeks later with severe abdominal pain, and IFN-alpha administration was discontinued. Considering the temporal relationship between the start of IFN-alpha treatment and development of acute pancreatitis, the absence of other clear etiologic factors for acute pancreatitis, disappearance of symptoms after discontinuation of IFN-alpha, and positive reactions to rechallenge, IFN-alpha is the most probable cause for development of acute pancreatitis in these patients. [less ▲]

Detailed reference viewed: 24 (2 ULg)
Peer Reviewed
See detailTreatment of acute hepatitis C with interferon alpha 2b prevents chronicity.
Delwaide, Jean ULg; Bourgeois, N.; Gerard, Christiane ULg et al

in Gut (2000), 47(3), 14

Detailed reference viewed: 15 (0 ULg)
Peer Reviewed
See detailTreatment of acute hepatitis C with interferon alpha-2b prevents chronicity.
Delwaide, Jean ULg; Bourgeois, N.; Gerard, Christiane ULg et al

in Hepatology (Baltimore, Md.) (1999), 30(4), 413

Detailed reference viewed: 14 (0 ULg)
Peer Reviewed
See detailDaily induction treatment with alpha 2b interferon in naive chronic hepatitis C patients results in a higher early response. A controlled multicenter randomized trial.
Van Vlierberghe, H.; Leroux-Roels, G.; Bourgeois, N. et al

in Hepatology (Baltimore, Md.) (1999), 30(4), 1884

Detailed reference viewed: 12 (0 ULg)
Full Text
Peer Reviewed
See detailPériartérite noueuse en relation avec une hépatite B
Demolin, G.; Delwaide, Jean ULg; Van Severen, M. et al

in Revue Médicale de Liège (1999), 54(1), 921-924

A 66-year-old man was hospitalized for asthenia, weight loss, fever and chills. A polyarteritis nodosa associated with hepatitis B virus infection in a replicative phase was diagnosed. Etiology ... [more ▼]

A 66-year-old man was hospitalized for asthenia, weight loss, fever and chills. A polyarteritis nodosa associated with hepatitis B virus infection in a replicative phase was diagnosed. Etiology, physiopathology, and clinical characteristics of hepatitis B virus-related polyarteritis nodosa will be reviewed, as well as the effectiveness of therapy combining corticosteroids, interferon alpha and plasma exchanges. [less ▲]

Detailed reference viewed: 46 (3 ULg)
Peer Reviewed
See detailHas disinfection of endoscopes by automatic machines become obligatory?
Delwaide, Jean ULg; Pelckmans, P.; Defrance, P. et al

in Revue Médicale de Bruxelles (1999), 20(1), 49-50

Detailed reference viewed: 7 (0 ULg)
Full Text
Peer Reviewed
See detailLiver transplantation in a Jehovah's witness
Detry, Olivier ULg; Honoré, Pierre ULg; Delwaide, Jean ULg et al

in Lancet (1999), 353

Detailed reference viewed: 42 (13 ULg)
Full Text
Peer Reviewed
See detailLa transmission du virus de l’hépatite C en milieu hospitalier
Delwaide, Jean ULg; Gerard, Christiane ULg; Belaiche, Jacques ULg et al

in Médecine et Hygiène (1999), 57

Detailed reference viewed: 37 (8 ULg)
Full Text
Peer Reviewed
See detailHepatitis C virus transmission following invasive medical procedures
Delwaide, Jean ULg; Gerard, Christiane ULg; Vaira, Dolorès ULg et al

in Journal of Internal Medicine (1999), 245(1), 107-108

Detailed reference viewed: 58 (7 ULg)